We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA needs stronger enforcement policies to stop the “common and dangerous” problem of false and misleading advertising by prescription drug marketers, according to a report released by the U.S. Public Interest Research Group (PIRG).